Tovaxin, radiation-attenuated, patient-specific T-cells for the therapeutic vaccination of multiple sclerosis.
Opexa Pharmaceuticals Inc is developing Tovaxin, a trivalent formulation of attenuated myelin-peptide-reactive T-cells, for the potential treatment of multiple sclerosis. Tovaxin is being evaluated in phase II clinical trials. Opexa was previously investigating Tovaxin for the potential treatment of rheumatoid arthritis; however, no development has been reported for this indication since December 2002.
Hellings
Niels
N
Hasselt University, Biomedical Research Institute, Agoralaan Building A, Diepenbeek B-3590, Belgium. niels.hellings@uhasselt.be
Stinissen
Piet
P
D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D006801:Humans; D009103:Multiple Sclerosis / Q000276:immunology / Q000628:therapy*; D004676:Myelin Basic Protein / Q000276:immunology*; D009185:Myelin Proteins; D018991:Myelin Proteolipid Protein / Q000276:immunology*; D018992:Myelin-Associated Glycoprotein / Q000276:immunology*; D063308:Myelin-Oligodendrocyte Glycoprotein; D013601:T-Lymphocytes / Q000276:immunology* / Q000528:radiation effects; D050378:T-Lymphocytes, Regulatory / Q000276:immunology; D014611:Vaccination; D014612:Vaccines / Q000276:immunology / Q000528:radiation effects
C571326:MOG protein, human; D004676:Myelin Basic Protein; D009185:Myelin Proteins; D018991:Myelin Proteolipid Protein; D018992:Myelin-Associated Glycoprotein; D063308:Myelin-Oligodendrocyte Glycoprotein; D014612:Vaccines